SCHEMBL10275635

SCHEMBL10275635

Nc1nc(-c2ccc(F)c(OC(F)(F)F)c2F)cs1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MPL P40238 6/20 0.64
HSD17B10 Q99714 3/20 0.43
TYR P14679 1/20 0.42
ALDH1A1 P00352 6/20 0.41
RAB9A P51151 4/20 0.41
ALOX5 P09917 1/20 0.41
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
KDM4E B2RXH2 3/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
NPC1 O15118 2/20 0.40
MAPT P10636 3/20 0.38
ALOX5AP P20292 1/20 0.37
FEN1 P39748 1/20 0.37
LTA4H P09960 2/20 0.37
POLB P06746 1/20 0.36
THRB P10828 1/20 0.35
ALOX15 P16050 1/20 0.35
PPARG P37231 1/20 0.35
NCOA2 Q15596 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10275178 0.82 MPL (0.77) MPLHSD17B10TYRALDH1A1RAB9A
SCHEMBL10275307 0.79 MPL (0.50) MPLHSD17B10TYRALDH1A1RAB9A
SCHEMBL474342 0.79 MPL (0.61) MPLHSD17B10TYRALDH1A1RAB9A
SCHEMBL474187 0.79 MPL (0.60) MPLHSD17B10TYRALDH1A1RAB9A
SCHEMBL29689702 0.79 MPL (0.60) MPLHSD17B10TYRALDH1A1RAB9A
SCHEMBL10275056 0.78 MPL (0.63) MPLHSD17B10TYRALDH1A1RAB9A
SCHEMBL4876821 0.78 MPL (1.00) MPLHSD17B10ALDH1A1RAB9AALOX5
SCHEMBL1802937 0.76 MPL (0.60) MPLHSD17B10TYRALDH1A1RAB9A
SCHEMBL474214 0.75 MPL (0.56) MPLHSD17B10TYRALDH1A1RAB9A
SCHEMBL10087321 0.75 MPL (0.56) MPLHSD17B10TYRALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2411395-B1 FUROPYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS GLENMARK PHARMACEUTICALS SA (CH) 2013-05-29 EP disclosed
US-20120178766-A1 FUROPYRIMIDINEDIONE DERIVATIVES AS TRPAI MODULATORS GLENMARK PHARMACEUTICALS S.A. (CH) 2012-07-12 US disclosed
US-20120178766-A1 FUROPYRIMIDINEDIONE DERIVATIVES AS TRPAI MODULATORS GLENMARK PHARMACEUTICALS S.A. (CH) 2012-07-12 US disclosed
WO-2010109329-A1 FUROPYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS GLENMARK PHARMACEUTICALS, S.A. (CH) 2010-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178766-A1 FUROPYRIMIDINEDIONE DERIVATIVES AS TRPAI MODULATORS TRPA1, TRPV1, TRPC3 MPL 3150/4885HSD17B10 3242/4885TYR 498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.